

SANOFI-AVENTIS  
Form 6-K  
October 01, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**  
**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September 2010

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In September 2010, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 to 99.10 which are incorporated herein by reference.

**Exhibit List**

| <u>Exhibit No.</u> | <u>Description</u>  |
|--------------------|---|
| Exhibit 99.1       | Press release dated August 26, 2010: Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox®  |
| Exhibit 99.2       | Press release dated August 29, 2010: Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation   |
| Exhibit 99.3       | Press release dated August 30, 2010: Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patients  |
| Exhibit 99.4       | Press release dated September 20, 2010: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 Diabetes     |
| Exhibit 99.5       | Press release dated September 20, 2010: Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes                                 |
| Exhibit 99.6       | Press release dated September 21, 2010: Sanofi-aventis presents its innovative blood glucose monitoring devices to enhance self-management of diabetes                                |
| Exhibit 99.7       | Press release dated September 22, 2010: Clinical Update on TAMARIS Phase III Trial for NV1FGF   |
| Exhibit 99.8       | Press release dated September 23, 2010: Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology |
| Exhibit 99.9       | Press release dated September 27, 2010: Sanofi Pasteur to Acquire VaxDesign, a U.S. biotechnology company   |
| Exhibit 99.10      | Press release dated September 30, 2010: Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose Control                             |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 1st, 2010

SANOFI-AVENTIS

By                    /S/ John Felitti  
Name: John Felitti  
Title: Associate Vice President,  
Corporate Law, Financial &  
Securities Law

**Exhibit Index**

| <u>Exhibit No.</u> | <u>Description</u>  |
|--------------------|---|
| Exhibit 99.1       | Press release dated August 26, 2010: Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox®  |
| Exhibit 99.2       | Press release dated August 29, 2010: Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation   |
| Exhibit 99.3       | Press release dated August 30, 2010: Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patients  |
| Exhibit 99.4       | Press release dated September 20, 2010: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 Diabetes     |
| Exhibit 99.5       | Press release dated September 20, 2010: Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes                                 |
| Exhibit 99.6       | Press release dated September 21, 2010: Sanofi-aventis presents its innovative blood glucose monitoring devices to enhance self-management of diabetes                                |
| Exhibit 99.7       | Press release dated September 22, 2010: Clinical Update on TAMARIS Phase III Trial for NV1FGF   |
| Exhibit 99.8       | Press release dated September 23, 2010: Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology |
| Exhibit 99.9       | Press release dated September 27, 2010: Sanofi Pasteur to Acquire VaxDesign, a U.S. biotechnology company   |
| Exhibit 99.10      | Press release dated September 30, 2010: Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose Control                             |